MAP3K12/DLK/Pref-1

Mitogen-activated protein kinase kinase kinase 12 (MAP3K12, also known as Dual Leucine Zipper Kinase, DLK) is a serine/threonine kinase regulating neuronal development and axon regeneration^[1][2][3]. DLK mediates stress-responsive signaling by activating the c-Jun N-terminal kinase (JNK) pathway, which in turn modulates apoptotic and regenerative transcriptional programs^[4][5][6]. Mechanistically, DLK forms complexes with scaffolding proteins such as JIP1 to control JNK activation, and its activity is further modulated by palmitoylation, subcellular localization, and protein-protein interactions^[3][7]. In disease models, DLK is upregulated in neurodegenerative conditions, Alzheimer's disease, and age-related hearing loss, promoting cell death via excessive autophagy and apoptosis^[7][8][9]. In contrast, in postnatal pancreatic beta cells, DLK/JNK3 signaling enhances cell proliferation and metabolic adaptation, demonstrating context-dependent functionality^[10][11]. Compared with the closely related isoform LZK, DLK activation triggers rapid degeneration in Purkinje neurons, while LZK induces slower degeneration, highlighting isoform-specific kinetics and cellular outcomes^[5]. Small-molecule inhibitors of DLK, including ATP-competitive compounds and palmitoylation blockers, have shown efficacy in modulating neurodegenerative processes and injury-induced apoptosis in preclinical models^[1][7][12]. Therefore, DLK serves as a versatile node in both injury-induced and developmental signaling, with potential for therapeutic targeting and experimental modulation.